On Friday the food and drug administration approved the drug called Otezla (apremilast) for treating arthritis associated with psoriasis. The medication made by Celgene Corporation is a pill while all other treatments of this condition are injections.
According to Bloomberg Businessweek the painful arthritic joint condition occurs in 30 percent of the 125 million people worldwide who suffer from the skin condition, psoriasis. Sales of medications to treat the condition are in the billions. Analysts estimate that by 2017 Otezla sales alone could surpass one billion.
According to The Wall Street Journal Dr. Philip Mease, Director of the Rheumatology Clinical Research Division of Swedish Medical Center, said, "OTEZLA works differently from other therapies approved for psoriatic arthritis through the intracellular inhibition of PDE4. The approval of an oral therapy with a novel mechanism of action for patients with psoriatic arthritis offers a different approach to patient care."
Testing of the pill yielded consistent results proving the medication to be safe and successful in treating affected patients.
There has been a critical error on your website.<\/p>
Learn more about debugging in WordPress.<\/a><\/p>","data":{"status":500},"additional_errors":[]}